Disclosed is a method for treating symptoms of diabetes using an agonist of the .alpha.2B and/or .alpha.2C adrenergic receptor subtypes that lacks (a) significant .alpha.2A adrenergic receptor activity or (b) significant .alpha.1A adrenergic receptor activity, or that lacks both (a) and (b).